Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Sell
33
MIST Quote, Financials, Valuation and Earnings
Last price:
$1.94
Seasonality move
:
-13.63%
Day range:
$1.75 - $1.90
52-week range:
$1.12 - $2.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.01x
Volume:
1.7M
Avg. volume:
1.2M
1-year change:
17.21%
Market cap:
$96.3M
Revenue:
$1M
EPS (TTM):
-$0.81
Analysts' Opinion
-
Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.25, Milestone Pharmaceuticals has an estimated upside of 467.87% from its current price of $1.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.81.
Fair Value
-
According to the consensus of 2 analysts, Milestone Pharmaceuticals has 467.87% upside to fair value with a price target of $10.25 per share.
MIST vs. S&P 500
-
Over the past 5 trading days, Milestone Pharmaceuticals has overperformed the S&P 500 by 13.35% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Milestone Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Milestone Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Milestone Pharmaceuticals reported revenues of --.
Earnings Growth
-
Milestone Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Milestone Pharmaceuticals reported earnings per share of -$0.14.
Enterprise value:
72.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-2.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$62.8M | -$61.1M | -$43.6M | -$15.4M | -$9.6M | |
| EBITDA | -$62.1M | -$57.5M | -$39.1M | -$14.2M | -$8.5M | |
| Diluted EPS | -$1.46 | -$1.38 | -$0.81 | -$0.35 | -$0.14 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $107.4M | $132.8M | $82.9M | $84.8M | $81M | |
| Total Assets | $108.8M | $133.8M | $85.8M | $87.1M | $82.7M | |
| Current Liabilities | $5.9M | $5.8M | $6.5M | $8.1M | $5.3M | |
| Total Liabilities | $6.6M | $6.4M | $8.6M | $58.6M | $58.7M | |
| Total Equity | $102.2M | $127.4M | $77.2M | $28.5M | $24M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$52M | -$49.5M | -$31.8M | -$12.2M | -$7M | |
| Cash From Investing | -$25.1M | -$25.9M | $2.6M | -$10.9M | $6.5M | |
| Cash From Financing | $3M | $48M | $32.1M | $305K | $74K | |
| Free Cash Flow | -$52.1M | -$49.7M | -$31.8M | -$12.2M | -$7M | |
MIST
Sector
Market Cap
$96.3M
$36.4M
Price % of 52-Week High
65.64%
45.1%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
17.21%
-39.83%
Beta (5-Year)
1.835
0.773
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.77
200-day SMA
Buy
Level
$1.67
Bollinger Bands (100)
Sell
Level
1.63 - 2.11
Chaikin Money Flow
Buy
Level
5M
20-day SMA
Sell
Level
$1.98
Relative Strength Index (RSI14)
Sell
Level
43.53
ADX Line
Sell
Level
25.94
Williams %R
Neutral
Level
-53.0769
50-day SMA
Sell
Level
$2.03
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
186.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.9368)
Sell
CA Score
(Annual)
Level (-3.6479)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (5.8973)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Stock Forecast FAQ
In the current month, MIST has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MIST average analyst price target in the past 3 months is $10.25.
-
Where Will Milestone Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Milestone Pharmaceuticals share price will rise to $10.25 per share over the next 12 months.
-
What Do Analysts Say About Milestone Pharmaceuticals?
Analysts are divided on their view about Milestone Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Milestone Pharmaceuticals is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Milestone Pharmaceuticals's Price Target?
The price target for Milestone Pharmaceuticals over the next 1-year time period is forecast to be $10.25 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MIST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Milestone Pharmaceuticals is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of MIST?
You can purchase shares of Milestone Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Milestone Pharmaceuticals shares.
-
What Is The Milestone Pharmaceuticals Share Price Today?
Milestone Pharmaceuticals was last trading at $1.94 per share. This represents the most recent stock quote for Milestone Pharmaceuticals. Yesterday, Milestone Pharmaceuticals closed at $1.81 per share.
-
How To Buy Milestone Pharmaceuticals Stock Online?
In order to purchase Milestone Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Is Walmart the Largest Retailer in the World?
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Stock Ideas
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
45
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
50
GH alert for Mar 12
Guardant Health [GH] is up 1.1% over the past day.
Sell
44
TER alert for Mar 12
Teradyne [TER] is down 0.36% over the past day.
Buy
57
LMB alert for Mar 12
Limbach Holdings [LMB] is down 4.39% over the past day.
